Finally, the AAV8-TR2-OriP-TK/GCV effectively suppressed the growth of KSHV-infected cancer cells in the xenograft tumor model, whereas systemic intravenous AAV8-TR2-OriP-TK injection/GCV showed no detectable side effects. The gene discussed is TKT; the disease is neoplasm.